Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

Terminated

Phase 3 Results

Summary of Purpose

The purpose of this study is to test whether the drug, atorvastatin, will be able to reduce the rate of return of the abnormal beats after using cardioversion. Atorvastatin is a drug approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol but is not approved for preventing abnormal... Trial Stopped: Insufficient power to show therapy difference at interim analysis.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 21 August 2014.

1 Oct 2005 14 Nov 2005 1 Nov 2008 1 Oct 2009 1 Aug 2014 21 Apr 2014
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Purpose: Prevention
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available